H.R. 3 included dozens of New Dem-led bills and provisions that reinvest savings in biomedical innovation, expand Medicare services for seniors, help combat opioid addiction, increase access to healthcare in underserved areas, and countless over provisions. Read below to see all the New Dem-led provisions that were included.

The New Dem-led bills included in this package are:

- **H.R. 4669**, the Maximizing Drug Coverage for Low-Income Seniors Act, to improve the enrollment process and lower out-of-pocket costs for low-income Medicare beneficiaries (Stevens, Sewell, Kuster)
- **Provision** to smooth out-of-pocket payments for Medicare Part-D beneficiaries (Sewell)
- **H.R. 4665**, the Medicare Vision Act, to add vision services to Medicare Part B coverage (Schrier, DelBene, O’Halleran, Slotkin)
- **H.R. 4632**, the Better Transparency in Information for Medicare Beneficiaries Act, to require CMS to send all low-income subsidy (LIS) enrollees with any premium liability a Chooser’s Notice (Kind, Davids)
- **H.R. 4618**, the Medicare Hearing Act, to add hearing services to Medicare Part B coverage (McBath)
- **H.R. 4655**, the Enhancing Retirement Security for Medicare Beneficiaries Act, to exclude monthly distributions from retirement accounts from the LIS income calculation (Lee)
- **H.R. 4620**, the More Help for Seniors Act, to expand the federal poverty level (FPL) threshold for the Medicare Part D LIS program qualification (Rose, Veasey, Morelle)
- **H.R. 4666**, legislation to amend LIS program availability in the U.S. territories (Shalala, Soto)
- **H.R. 4661**, the Advancing Enrollment and Reducing Drug Costs Act, to create LIS program automatic enrollment for certain seniors in Medicare (Pappas)
- **H.R. 4667**, the Biomedical Innovation Expansion Act, to dedicate new resources to the NIH Innovation Fund to support activities in rare diseases, antibiotic resistance, and more (Sherrill, Spanberger)
- **H.R. 2922**, the Respond NOW Act, to establish the Opioid Epidemic Respond Fund to allocate funds to the Substance Abuse and Mental Health Services Administration (SAMHSA), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the National Institutes of Health (NIH), the Health Resources and Services Administration (HRSA), and the Administration for Children and Families (ACF) (Kuster)
• H.R. 2466, the State Opioid Response Grant Authorization Act to extend funding for the State Opioid Response Grants program (Trone)
• H.R. 4649, the Capping Drug Costs for Seniors Act, to establish a $2,000 out-of-pocket cap on drug spending each year in Medicare Part D (Horsford, Horn)
• H.R. 4676, the Protecting Medicare Beneficiaries with Pre-Existing Conditions, Act to amend the Social Security Act to provide for the guaranteed issue of Medigap policies to all Medigap-eligible Medicare beneficiaries and Medicare Advantage enrollees (Schneider)
• H.R. 3924, the Streamlining Part D Appeals Process Act to provide for the treatment of a pharmacy counter refusal as a coverage determination under Medicare part D (Suozzi)
• H.R. 4455, the Bolstering Innovative Options to Save Immediately on Medicines (BIOSIM) Act to amend the Social Security Act to provide for a temporary payment increase under the Medicare program for certain biosimilar biological products to encourage the development and use of such products (Schrader)
• H.R. 4893, the Keeping Our Children Safe Act to provide increased funding for the Child Abuse Prevention and Treatment Act (CAPTA) (Wild)

Also included in this package are bills and provisions with NDC Members as original cosponsors:
• H.R. 4671, the Helping Seniors Afford Health Care Act, to expand and modify Medicare Savings Program eligibility and enrollment (Blunt Rochester)
• H.R. 4650, the Medicare Dental Act, to add dental services to Medicare Part B coverage (Horsford)
• H.R. 4619, the Pharmaceutical Rebates for Excessive Pricing Above Inflation Act, to create a rebate for drug prices that increase faster than inflation in Medicare Part D (Wild)
• H.R. 4663, the Freedom for Price Gouging Act, to create a rebate for drug prices that increase faster than inflation in Medicare Part B (Crow)
• H.R. 4675, the Language Access for Medicare Beneficiaries Act, to expand LIS application languages (Cárdenas)
• H.R. 4633, the Investing in Safety and Innovation Act, to dedicate new resources to the FDA Cures Innovation Fund to support drug development and more (Peters)
• H.R. 4835, the Supporting Trauma-Informed Education Practices Act, to provide grants to improve trauma support services and mental health care for children and youth in educational settings (Wild)

Amendments Adopted During Floor Consideration
• Amendment to create a pilot program to develop, expand, and enhance the commercialization of biomedical products (Peters, Cisneros)
• Amendment to create a grant program to cover the start-up costs of Graduate Medical Education (GME) programs in rural and medically underserved areas, including at Critical Access Hospitals (O’Halleran)

• Amendment to require a HHS study to identify conditions without an FDA-approved treatment where the development of a treatment would fill an unmet medical need for a serious or life-threatening condition or rare disease, and require HHS to identify appropriate incentives that would lead to the development of such treatments (Gottheimer)

• Amendment to establish a grant program for states to reduce the costs and burdens associated with health care administrative work (Axne)

• Amendment to clarify that federal employee health plans are covered by the price reduction provisions of the bill (Luria)

• Amendment to allow the Veteran’s Administration to benefit from Maximum Fair Pricing guidelines (Cunningham)